In this issue:
SOME PATHOLOGISTS AND LAB EXECUTIVES find the FDA’s latest actions regarding pharmacogenetic testing confusing, unclear and beyond the FDA’s authority. Other observers note that the FDA does indeed have a legitimate concern. THE DARK REPORT examines both sides of this controversy. Also reported is the opinion of respected pathology consultants that the result of deep fee cuts by Anthem to some anatomic pathology services will harm patients.